Pittsburgh-based Neoolife, Inc. is a pre-clinical Bio-MedTech startup developing tissue-engineered biomimetic heart valves and cardiovascular patches designed to support the body’s own tissue regeneration. Its distinctive Double Component Deposition technology creates non-animal-derived polymeric scaffolds, including the OneValveTric transcatheter tricuspid valve system, while the company’s international team brings more than 130 years of combined biomedical and cardiovascular experience. The technology has received support through NIH and European Research Council grants, but Neoolife’s products remain in research and pre-clinical development and are not yet approved by regulators.